go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Allergan Ltd

Allergan Ltd
Marlow International, The Parkway, Marlow, Bucks, SL7 1YL, UK
Telephone: +44 (0)1628 494444
Fax: +44 (0)1628 494449
Medical Information Direct Line: +44 (0)1628 494026
Medical Information e-mail: UK_Medinfo@allergan.com


Summary of Product Characteristics last updated on medicines.ie: 04/03/2009
SPC Celluvisc 1.0% w/v Eye drops, solution

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipient(s)
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Celluvisc 1% w/v Eye drops, solution, unit dose


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml contains 10 mg carmellose sodium.

One drop (≈ 0.05 ml) contains 0.5 mg of carmellose sodium.

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Eye drops, solution

A clear, colourless to slightly yellow viscous solution.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Treatment of the symptoms of dry eye.


Go to top of the page
4.2 Posology and method of administration

Instil one or two drops in the affected eye/s as needed.

Ensure that the single-dose container is intact before use. The eye drop solution should be used immediately after opening.

To avoid contamination do not touch the tip to the eye or any other surface.


Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

If irritation, pain, redness and changes in vision occur or worsen, treatment should be discontinued and a new assessment considered.

Contact lenses should be removed before each application and may be inserted after 15 minutes.

Concomitant ocular medication should be administered 15 minutes prior to the instillation of Celluvisc.

To avoid contamination, do not touch the tip to the eye or any surface. Discard open single dose container after use.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed

1. No interactions have been observed with Celluvisc. Given the formulation of Celluvisc, no interactions are anticipated.

2. If this product is used concomitantly with other topical eye medications there must be an interval of at least 15 minutes between the two medications.


Go to top of the page
4.6 Pregnancy and lactation

The constituents of Celluvisc have been used as pharmaceutical agents for many years with no untoward effects. No special precautions are necessary for the use of Celluvisc in pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

Celluvisc has minor or moderate influence on the ability to drive and use machines as it may cause transient blurring of vision. Do not drive or use machinery unless vision is clear.


Go to top of the page
4.8 Undesirable effects

The frequency of undesirable effects is defined as follows: Very Common (GREATER-THAN OR EQUAL TO (8805) 1/10) Common (GREATER-THAN OR EQUAL TO (8805)1/100, <1/10) Uncommon (GREATER-THAN OR EQUAL TO (8805)1/1,000, <1/100) Rare (GREATER-THAN OR EQUAL TO (8805)1/10,000, <1/1,000) Very Rare (<1/10,000), not known (cannot be estimated from the available data).

Eye disorders:

Not known: eye irritation, eye pain, vision blurred, lacrimation increased.


Go to top of the page
4.9 Overdose

Accidental overdose will present no hazard.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other ophthalmologicals

ATC code: S01XA20

Carmellose sodium has no pharmacological effect. Carmellose sodium has a high viscosity resulting in an increased retention time on the eye.


Go to top of the page
5.2 Pharmacokinetic properties

Due to the high molecular weight (approx. 90,000 Daltons) carmellose sodium is unlikely to penetrate the cornea.


Go to top of the page
5.3 Preclinical safety data

No additional information of relevance for the doctor has been obtained from the preclinical testing.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipient(s)

Sodium chloride

Sodium lactate

Potassium chloride

Calcium chloride

Purified water


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

2 years.

The eye drop solution should be used immediately after opening. Any unused solution should be discarded.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25ºC.


Go to top of the page
6.5 Nature and contents of container

Clear, single-dose containers made from low density polyethylene formed with a twist-off tab.

Each unit is filled with 0.4 ml of solution.

Pack sizes: 5, 10, 20, 30, 40, 60 or 90 single-dose containers.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

Ensure that the single dose container is intact before use. Discard any unused solution (i.e. once opened do not re-use container for subsequent doses).


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Allergan Pharmaceuticals Ireland

Castlebar Road

Westport

Co. Mayo


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 148/59/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 23rd April 1997

Date of last renewal: 3rd October 2008


Go to top of the page
10. DATE OF REVISION OF THE TEXT

13th February 2009



Link to this document from your website:
http://www.medicines.ie/medicine/2604/SPC/Celluvisc+1.0++w+v+Eye+drops%2c+solution/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

 
   Carmellose sodium

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo